Literature DB >> 27704472

[Revival after Ebola: multidisciplinary assessment at 1 year, prospect and follow-up study of surviving patients from Ebola in Guinea (PostEboGui cohort)].

P Msellati1,2, A Touré3,4, M S Sow5, K Cécé3, B Taverne3, A Desclaux3, M Barry5, J-F Etard3, E Delaporte3.   

Abstract

Ebola virus disease (EVD) epidemic that spread in West Africa from the end of 2013 to early 2016 has reached more people than all past epidemics. Beyond care management of acute phase ill patients and measures for the control of the epidemic, the outcome of Ebola survivors became an important question as their number increased and raised new issues. A multidisciplinary prospective cohort of survivors in Guinea has been launched by IRD UMI 233 and Donka National Hospital, Conakry, Guinea, to assess the long-term clinical, psychological, sociological, immunological, and viral outcomes potentially related to EVD. This paper describes PostEboGui Programme, constraints and changes to the initial proposal, participants, first results, and new issues, 1 year after its start, in a descriptive and critical view. We started also to work on ethical aspects in the context of epidemics and of mass interventions with a risk of overinvestigation of patients.

Entities:  

Keywords:  Cohort; Ebola; Guinea; PostEboGui; Sub-Saharan Africa; Survivors

Mesh:

Year:  2016        PMID: 27704472     DOI: 10.1007/s13149-016-0526-x

Source DB:  PubMed          Journal:  Bull Soc Pathol Exot        ISSN: 0037-9085


  1 in total

1.  Long-lasting severe immune dysfunction in Ebola virus disease survivors.

Authors:  Aurélie Wiedemann; Emile Foucat; Hakim Hocini; Cécile Lefebvre; Boris P Hejblum; Mélany Durand; Miriam Krüger; Alpha Kabinet Keita; Ahidjo Ayouba; Stéphane Mély; José-Carlos Fernandez; Abdoulaye Touré; Slim Fourati; Claire Lévy-Marchal; Hervé Raoul; Eric Delaporte; Lamine Koivogui; Rodolphe Thiébaut; Christine Lacabaratz; Yves Lévy
Journal:  Nat Commun       Date:  2020-07-24       Impact factor: 14.919

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.